LNTH READ THE FULL LNTH RESEARCH REPORT As 2026 begins, we are updating investors on Lantheus Holdings, Inc. (NASDAQ:LNTH), ...

On a YTD basis, Lantheus is outperforming its medical equipment peers by 3x; this wasn't the case until July, when the CMS came out with a new proposal. Even before the CMS' proposal, PYLARIFY was ...

PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with ...

Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) reported third quarter 2025 financial and operational results on November 6 th, producing sales of $384 million, a 1% increase compared to 3Q:24 levels. Pylarify ...

PYLARIFY has made a profound impact on the lives of patients battling prostate cancer. It is the number one ordered PSMA PET imaging agent in the U.S., and is a proven diagnostic backed by real-world ...

The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection. The Food and Drug Administration (FDA) ...

Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes ...

(RTTNews) - Lantheus Holdings Inc. (LNTH) and GE HealthCare (GEHC) announced an exclusive licensing agreement under which GE HealthCare will develop, manufacture, and commercialize Lantheus' ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved piflufolastat F 18 injection, a radioactive diagnostic agent designed to identify suspected ...